|
Oct 3
|
Harrow Relaunches TRIESENCE®
|
|
Oct 2
|
Harrow, Inc. (HROW): A Bull Case Theory
|
|
Sep 25
|
Harrow Announces Nashville Expansion
|
|
Aug 7
|
Harrow Announces Second Quarter 2024 Financial Results
|
|
Jul 25
|
Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024
|
|
Jun 20
|
Harrow Provides TRIESENCE® Relaunch Update
|
|
May 15
|
Harrow to Present at Two Investor Conferences in May
|
|
May 13
|
Harrow Announces First Quarter 2024 Financial Results
|
|
May 13
|
Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial
|
|
Apr 25
|
Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024
|
|
Apr 2
|
Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing
|
|
Mar 21
|
Harrow Health, Inc. (NASDAQ:HROW) Q4 2023 Earnings Call Transcript
|
|
Mar 19
|
Harrow Inc (HROW) Reports Substantial Revenue Growth Amidst Net Loss Expansion in 2023
|
|
Mar 19
|
Harrow Announces Fourth Quarter and Year-End 2023 Financial Results
|
|
Mar 13
|
Harrow (HROW) Fell on Lowering the Guidance
|
|
Mar 5
|
Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024
|
|
Feb 15
|
Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products
|
|
Jan 11
|
Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease
|
|
Jan 3
|
Melt Pharmaceuticals Provides Corporate Update
|
|
Jan 3
|
Harrow Partners with Leading Healthcare Market Access Technology Platforms
|